Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01
This study follows people with Parkinson's disease who previously received a treatment called BRT-DA01 in an earlier trial. The main goal is to continue monitoring their health and how their Parkinson's symptoms are progressing for up to five years after they had the treatment. It's important to know that participants in this specific study won't be given any new experimental treatment; instead, researchers are just observing the long-term effects of the BRT-DA01 treatment they received previously. The study aims to gather more information on the safety and potential benefits of BRT-DA01 over a longer period. This will help doctors understand more about how this treatment works as people live with Parkinson's.
At a glance
What is this study about?
This study is designed to keep a close eye on people who have Parkinson's disease and previously took part in an earlier study where they received a special treatment called BRT-DA01. Think of it like a long-term follow-up. The researchers aren't giving any new experimental treatments in this study; they're simply checking in with participants to see how they've been doing since their original treatment.
The main purpose is to learn more about the long-term effects of BRT-DA01. Researchers want to understand its safety over several years and how it might impact the ongoing symptoms of Parkinson's disease. By continuing to gather information, doctors can better understand if the treatment has lasting benefits or any side effects that might appear over time.
This kind of follow-up study is really important because it helps scientists get a complete picture of a new treatment. Knowing what happens to people years after they receive a treatment provides valuable insights that can help improve care for others with Parkinson's disease in the future. It helps ensure that treatments are not only effective but also safe in the long run.
Key takeaways
- This study is a long-term follow-up for people who already had BRT-DA01 treatment.
- No new experimental treatments will be given in this study.
- Researchers will monitor your health and Parkinson's symptoms for up to five years.
- The main goal is to understand the long-term safety and effects of BRT-DA01.
- You must have participated in the previous BRT-DA01 study to be eligible.
Who may be eligible?
To be part of this study, you need to have previously participated in an earlier study where you received the BRT-DA01 treatment for Parkinson's disease. You would have either completed that earlier study or stopped participating for some reason.
It's also essential that you are willing to give written permission to join this new study. This means you understand what's involved and agree to attend all the study check-ups and follow the study instructions.
There are no specific reasons that would stop someone from joining this study, as long as they fit the points mentioned above. Participants should be between 50 and 78 years old, and the study is open to both men and women.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Did you take part in the earlier BRT-DA01 study for Parkinson's disease?
- Are you willing to sign a consent form to join this new follow-up study?
- Are you between 50 and 78 years old?
- Can you attend regular check-up appointments for up to five years?
What does participation involve?
If you decide to take part in this study, you won't be given any new medication or treatment. Instead, the study is all about monitoring your health and how your Parkinson's disease symptoms are over time. You will have regular check-ups over a period of up to five years from when you first received the BRT-DA01 treatment in the earlier study. These check-ups will involve things like talking to the study team about your health and any changes you've noticed, and possibly some physical assessments. The aim is to gather ongoing information about how you're doing after your previous treatment. The exact details of how often you'll need to visit and what each visit involves will be explained fully by the study team.
Potential risks and benefits
Locations (3)
- University of California, IrvineVerified postcodeOrange, United States
- Weill Cornell Medical CollegeVerified postcodeNew York, United States
- Toronto Western HospitalVerified postcodeToronto, Canada
Common questions
What is BRT-DA01?
BRT-DA01 is a treatment for Parkinson's disease that you received in an earlier study. This new study is about observing its long-term effects.
Will I receive any new treatment in this study?
No, you will not receive any new experimental treatments in this study. It's purely for observation and follow-up.
How long will I be in this study?
You will be monitored for up to five years from the time you received the BRT-DA01 treatment in the previous study.
What do I need to do to join?
You need to have been part of the previous BRT-DA01 study and be willing to give written permission to take part in this follow-up.
What is the age limit for this study?
Participants must be between 50 and 78 years old.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.